You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy

    SBC: NEWVENTUREIQ LLC            Topic: 102

    Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Orally Available Therapeutic for Neutralizing C. difficile Toxin B

    SBC: NECTAGEN INC            Topic: NIAID

    Infection with the bacterium C. difficile is the most common and increasingly prevalent cause of diarrhea. In the United States, cases of C. difficile infection (CDI) are estimated to number 500,000 annually and to result in an estimated 15,000 to 30,000 deaths. The cost of these cases is thought to exceed $4.8 billion annually. CDI continues to cause discomfort, serious illness and sometimes deat ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. 3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring

    SBC: Axioforce LLC            Topic: NIBIB

    PROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Developing a clinical diagnostic tool for age-related cochlear synaptopathy.

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIA

    Age-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma

    SBC: Sarya, LLC            Topic: 102

    PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. STARTUP Central

    SBC: CONTINUUM EDUCATIONAL TECHNOLOGIES, PBC            Topic: 500

    PROJECT SUMMARY Continuum Educational Technologies’ (Continuum) will work with the University of Kansas (KU) on the proposed I-RED program entitled Smart Tools to Accelerate Research Translation by Uplifting Participants for the Central IDeA State Region (STARTUP Central) program to stimulate technological innovation in the IDeA state regions by addressing the entrepreneurial educational needs o ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Cooperative Control and Localization of Multiple Spacecraft using a Multi-Agent Mission Operations System

    SBC: INTERSTEL TECHNOLOGIES INC            Topic: T4

    Multi-satellite swarms are becoming very popular due to their low costs and short development time. Instead of large and costly monolithic satellites, small satellite swarms can be flown as distributed sensing platforms for atmospheric sampling, distributed antennas, and synthetic apertures among other exciting applications, delivering an even greater mission capability. This project contributes t ...

    STTR Phase II 2022 National Aeronautics and Space Administration
  8. Mitofusin Agonists to Treat Neurodegenerative Disease

    SBC: Mitochondria in Motion, Inc.            Topic: 104

    Mitofusin agonists for the treatment of neurodegenerative diseases Gerald W Dorn II, MD Mitochondria in Motion, Inc. Washington University in St Louis School of Medicine Abstract: A number of rare neurodegenerative diseases are characterized by mitochondrial fragmentation, dysmotility and dysfunction. Among these are Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD), which cause ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (h ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection

    SBC: FORWARD DEFENSE, LLC            Topic: NIAID

    PROJECT SUMMARY Staphylococcus aureus is an aggressive antibiotic-resistant human bacterial pathogen. S. aureus is a leading cause of infectious disease morbidity, mortality, and hospital-associated infection in the U.S., and a formidable health threat worldwide. Given the rapid acquisition of drug resistance by S. aureus, universal vaccination has been a premier goal in the field to provide a dur ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government